CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Study ID
NCT05623150
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liver biopsy — DIAGNOSTIC_TEST
    Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.

Study Details

The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic steatosis/Non-Alcoholic SteatoHepatitis. The investigators will include patients with and without cirrhosis in order to identify early molecular mechanisms involved in the development of HCC especially in non-cirrhotic patients.

Key Dates

First listed
Nov 21, 2022
Start date
Dec 6, 2022
Status verified
Apr 2026
Primary completion
Jan 31, 2032
Completion
Mar 31, 2032

Study Design

Enrollment
710 participants (estimated)

Arms

  • Arm: Descriptive study
    The patients included in this observational study are patients with hepatic steatosis either related to NAFLD or to alcohol-related liver disease. Patients included in the study may have hepatocellular carcinoma. Thus, 4 groups of patients can be recruited: * patients with NAFLD without hepatocellular carcinoma, * patients with NAFLD with hepatocellular carcinoma, * patients with alcohol-related liver disease without hepatocellular carcinoma, -patients with alcohol-related liver disease with hepatocellular carcinoma.

Primary Outcome Measure

Primary outcome measure CHALNA2 [ Time Frame: 2022-2032 ]

Central Contacts

Find similar trials

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials

Related Studies